ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
(NasdaqGM:AVBP),(NasdaqGM:AVBP), NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu […]